Brought to you by

Eisai promotes Pfizer's Fragmin in the US
30 Sep 2005
Executive Summary
Pfizer licensed Eisai Inc. exclusive rights to promote its Fragmin (dalteparin sodium) injectable anticoagulant in the US.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com